These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37812895)

  • 1. Oleanolic acid alleviates the extrapyramidal symptoms and cognitive impairment induced by haloperidol through the striatal PKA signaling pathway in mice.
    Kong CH; Cho K; Min JW; Kim JY; Park K; Kim DY; Jeon M; Kang WC; Jung SY; Lee JY; Ryu JH
    Biomed Pharmacother; 2023 Dec; 168():115639. PubMed ID: 37812895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
    Sonego AB; Prado DDS; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110367. PubMed ID: 34048863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
    Bordia T; McIntosh JM; Quik M
    J Pharmacol Exp Ther; 2012 Mar; 340(3):612-9. PubMed ID: 22144565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
    Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
    Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
    Arora D; Mudgal J; Nampoothiri M; Mallik SB; Kinra M; Hall S; Anoopkumar-Dukie S; Grant GD; Rao CM
    Metab Brain Dis; 2018 Aug; 33(4):1045-1051. PubMed ID: 29516413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia.
    Röpke J; Ferreira-Vieira TH; Iglesias LP; Asth L; Ribeiro FM; Moreira FA
    Pharmacol Biochem Behav; 2021 Jul; 206():173193. PubMed ID: 33933537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
    Sonego AB; Gomes FV; Del Bel EA; Guimaraes FS
    Behav Brain Res; 2016 Aug; 309():22-8. PubMed ID: 27131780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
    Varty GB; Hodgson RA; Pond AJ; Grzelak ME; Parker EM; Hunter JC
    Psychopharmacology (Berl); 2008 Oct; 200(3):393-401. PubMed ID: 18594798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.
    Wolf WA; Bieganski GJ; Guillen V; Mignon L
    Psychopharmacology (Berl); 2005 Oct; 182(1):84-94. PubMed ID: 15986194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice.
    Turalba AV; Leite-Morris KA; Kaplan GB
    Neurosci Lett; 2004 Feb; 357(1):53-7. PubMed ID: 15036612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
    Tatara A; Shimizu S; Shin N; Sato M; Sugiuchi T; Imaki J; Ohno Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):252-9. PubMed ID: 22542492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
    Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
    Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy.
    Naidu PS; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2004 Jun; 26(5):323-6. PubMed ID: 15319809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.